Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: A before and after intervention study of carbapenem-use stewardship

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Yoon, Young Kyung ^a,b   Yang, Kyung Sook ^a   Lee, Seung Eun ^b   Kim, Hyun Jeong ^b   Sohn, Jang Wook ^a,b   Kim, Min Ja ^a,b  

^a Korea University College of Medicine   (South Korea)

^b College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PANIPENEM; ANTIINFECTIVE AGENT; BETA LACTAM; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG USE; HUMAN; IN VITRO STUDY; INFECTION CONTROL; INTERVENTION STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRESCRIPTION; UNIVERSITY HOSPITAL; ACINETOBACTER INFECTIONS; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; INTERVENTION STUDIES; MICROBIAL SENSITIVITY TESTS;

EID: 84902593557     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099101     Document Type: Article

References (27)

1. Peleg AY, Seifert H, Paterson DL (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21: 538-582.
2. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, et al. (2007) Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51: 3471-3484. (Pubitemid 47519332)
3. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, et al. (2007) Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13: 97-103. (Pubitemid 46057843)
4. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, et al. (2007) Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 28: 713-719.
5. Fishbain J, Peleg AY (2010) Treatment of Acinetobacter infections. Clin Infect Dis 51: 79-84.
6. Lee K, Yong D, Jeong SH, Chong Y (2011) Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J 52: 879-891.
7. Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC (2011) Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70: 150-153.
8. Kuo HY, Chang KC, Kuo JW, Yueh HW, Liou ML (2012) Imipenem: a potent inducer of multidrug resistance in Acinetobacter baumannii. Int J Antimicrob Agents 39: 33-38.
9. Falagas ME, Kopterides P (2006) Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 64: 7-15. (Pubitemid 44161380)
10. Yoon YK, Cheong HW, Pai H, Roh KH, Kim JY, et al. (2011) Molecular analysis of a prolonged spread of Klebsiella pneumonia co-producing DHA-1 and SHV-12 β-lactamases. J Microbiol 49: 363-368.
11. Goff DA, Mangino JE (2008) Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. J Infect 57: 123-127.
12. Beović B, Kreft S, Seme K, Cizman M (2011) Does ertepenem alter the susceptibility of Pseudomonas aeruginosa to carbapenems? J Chemother 23: 216-220.
13. Lima AL, Oliveira PR, Paula AP, Dal-Paz K, Rossi F, et al. (2009) The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect Control Hosp Epidemiol 30: 487-490.
14. Lima AL, Oliveira PR, Paula AP, Zumiotti AV (2008) Influence of ertapenem administration on the incidence of carbapenem-resistant Pseudomonas aeruginosa. Braz J Infect Dis 12: 105-106.
15. Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ (2013) Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review. Expert Rev Anti Infect Ther 11: 69-78.
16. Lee CM, Lai CC, Wang YY, Lee MC, Hsueh PR (2013) Impact of susceptibility profiles of Gram-negative bacteria before and after the introduction of ertapenem at a medical center in northern Taiwan from 2004 to 2010. Diagn Microbiol Infect Dis 75: 94-100.
17. Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, et al. (2012) Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents 39: 11-15.
18. McDougall DA, Morton AP, Playford EG (2013) Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia. J Antimicrob Chemother 68: 457-460.
19. Kim JY, Sohn JW, Park DW, Yoon YK, Kim YM, et al. (2008) Control of extended-spectrum {beta}-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use. J Antimicrob Chemother 62: 416-421. (Pubitemid 351984791)
20. Dortch MJ, Fleming SB, Kauffmann RM, Dossett LA, Talbot TR, et al. (2011) Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections. Surg Infect (Larchmt) 12: 15-25.
21. Chen IL, Lee CH, Su LH, Tang YF, Chang SJ, et al. (2013) Antibiotic consumption and healthcare-associated infections caused by multidrug-resistant gram-negative bacilli at a large medical center in Taiwan from 2002 to 2009: implicating the importance of antibiotic stewardship. PLoS One 8: e65621.
22. Lima AL, Oliveira PR, Paula AP, Dal-Paz K, Almeida JN Jr, et al. (2011) Carbapenem stewardship: positive impact on hospital ecology. Braz J Infect Dis 15: 1-5.
23. Cao J, Song W, Gu B, Mei YN, Tang JP, et al. (2013) Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. J Clin Pharmacol 53: 96-102.
24. Xu J, Sun Z, Li Y, Zhou Q (2013) Surveillance and correlation of antibiotic consumption and resistance of Acinetobacter baumannii complex in a tertiary care hospital in northeast China, 2003-2011. Int J Environ Res Public Health 10: 1462-1473.
25. Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, et al. (2012) Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One 7: e37788.
26. Sousa D, Castelo-Corral L, Gutiérrez-Urbón JM, Molina F, López-Calviño B, et al. (2013) Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology? J Antimicrob Chemother 68:1917-1925.
27. D'Agata EM, Thayer V, Schaffner W (2000) An outbreak of Acinetobacter baumannii: the importance of cross-transmission. Infect Control Hosp Epidemiol 21: 588-591.